Showing results (111-120 of 359) with videos related to
Sort By:
Pageof 36
The Journal of Allergy and Clinical Immunology|January 8, 2005
Allergic conjunctivitis: update on pathophysiology and prospects for future treatmentSanta Jeremy Ono, Mark B AbelsonCurrent Medical Research and Opinion|February 11, 2005
Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge modelMark B Abelson, Jack V GreinerAmerican Journal of Ophthalmology|February 1, 1981
Animal and human ocular surface response to a topical nonimmune mast-cell degranulating agent (compound 48/80)I J Udell, M B AbelsonActa Ophthalmologica Scandinavica. Supplement|May 25, 1999
The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge modelM B Abelson, R Q LanierClinical Therapeutics|April 16, 2002
A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge modelMark B Abelson, Allen P KaplanExpert Opinion on Drug Metabolism & Toxicology|April 25, 2008
Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosingMark B Abelson, Paul J GomesThe CLAO Journal : Official Publication of the Contact Lens Association of Ophthalmologists, Inc|April 1, 1993
Complications and symptoms with disposable daily wear contact lenses and conventional soft daily wear contact lensesE C Poggio, M B AbelsonAmerican Journal of Ophthalmology|June 1, 1977
A tentative mechanism for inferior punctate keratopathyM B Abelson, F J HollyExpert Review of Clinical Immunology|May 19, 2010
Pharmacology, clinical efficacy and safety of olopatadine hydrochlorideSteven J Lichtenstein, Mark B AbelsonArchives of Ophthalmology (Chicago, Ill. : 1960)|February 1, 1981
H2-receptors in the human ocular surfaceM B Abelson, I J UdellPageof 36